✦ LIBER ✦

OR54 Cutaneous plasmacytomas in a patient with refractory nonsecretory myeloma

✍ Scribed by C. Moreira; F. Carneiro; A. Espirito Santo; J.-M. Mariz

Book ID: 114339916
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 57 KB
Volume: 82
Category: Article
ISSN: 1040-8428
DOI: 10.1016/s1040-8428(12)70066-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pancreatic plasmacytomas in a patient wi

Pancreatic plasmacytomas in a patient with multiple myeloma: CT and ultrasound findings

✍ Mary C. Olson; Carl L. Kalbhen; Harold V. Posniak 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 586 KB

Extramedullary plasmacytomas are an unusual manifestation of multiple myeloma. They occur most frequently in tissues or organs rich in reticuloendothelial cells. Pancreatic plasmacytomas are rare, with only a few case reports in the literature. We present the ultrasound (US) and computed tomographic

Dural plasmacytoma mimicking meningioma

Dural plasmacytoma mimicking meningioma in a patient with multiple myeloma

✍ Fahri Sahin; Guray Saydam; Yesim Ertan; Cem Calli; Ayhan Dönmez; Murat Tombulogl 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 223 KB

Nonsecretory multiple myeloma in a 26-ye

Nonsecretory multiple myeloma in a 26-year-old man with acquired immunodeficiency syndrome, presenting with multiple extramedullary plasmacytomas and osteolytic bone disease

✍ Anand B. Karnad; Alvin W. Martin; Howard K. Koh; Mark J. Brauer; Marilyn Novich; 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 659 KB

Evolution of hepatosplenic plasmacytoma

Evolution of hepatosplenic plasmacytoma in a patient with multiple myeloma receiving chemotherapy

✍ Pankaj Malhotra; Pradeep Bhat; Sushil Mahi; Sandeep Chauhan; Arvind Rajwanshi; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 2 views

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Choroidal plasmacytoma in a patient with

Choroidal plasmacytoma in a patient with multiple myeloma. Diagnosis by fine-needle aspiration biopsy

✍ Melis Palamar; Carol L. Shields; Fariba Ghassemi; Hormoz Ehya; Jerry A. Shields 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 132 KB